Bicycle Therapeutics: Executive Compensation & Equity Awards Detailed
Ticker: BCYC · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1761612
Sentiment: neutral
Topics: executive-compensation, equity-awards, proxy-statement
TL;DR
Bicycle Therapeutics DEF 14A shows exec comp details for 2024 - equity awards, fair values, and prior year changes.
AI Summary
Bicycle Therapeutics plc filed a DEF 14A on April 23, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity awards granted to its principal executive officers (PEO) and non-PEO named executive officers. It includes information on the year-end fair value of outstanding and unvested equity awards for 2024, as well as changes in the fair value of awards granted in prior years.
Why It Matters
This filing provides transparency into how Bicycle Therapeutics compensates its top executives, which can influence investor perception of management alignment and company strategy.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation, which typically carries low risk.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 2023 — Fiscal Year (Comparative data for executive compensation.)
- 2022 — Fiscal Year (Comparative data for executive compensation.)
- 2021 — Fiscal Year (Comparative data for executive compensation.)
Key Players & Entities
- Bicycle Therapeutics plc (company) — Filer
- 0001761612 (company) — Central Index Key
- 20250423 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the total reported compensation for the Principal Executive Officer (PEO) in 2024?
The filing provides data on the year-end fair value of equity awards granted, outstanding, and unvested for PEOs and Non-PEO Neo members for the fiscal year 2024, but does not explicitly state a single total compensation dollar amount in the provided snippet.
When was this DEF 14A filing submitted to the SEC?
The filing was submitted on April 23, 2025.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing is a proxy statement filed by companies to provide shareholders with information they need to vote on certain matters at shareholder meetings, often including executive compensation details.
What specific types of equity awards are detailed in the filing for 2024?
The filing details the year-end fair value of equity awards granted in the covered year that are outstanding and unvested, as well as changes in the fair value of outstanding and unvested equity awards granted in prior years.
What is the fiscal year end for Bicycle Therapeutics plc?
The fiscal year end for Bicycle Therapeutics plc is December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding BICYCLE THERAPEUTICS PLC (BCYC).